Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
51.55
+0.15 (0.29%)
Apr 30, 2025, 5:35 PM CET
Market Cap 2.64B
Revenue (ttm) 763.75M
Net Income (ttm) 136.88M
Shares Out 51.15M
EPS (ttm) 2.67
PE Ratio 19.29
Forward PE 20.35
Dividend 0.94 (1.81%)
Ex-Dividend Date Jul 8, 2024
Volume 5,760
Average Volume 121,749
Open 51.70
Previous Close 51.40
Day's Range 51.20 - 52.25
52-Week Range 45.52 - 94.80
Beta 0.47
RSI 54.46
Earnings Date May 9, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,197
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements

News

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating ...

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

2 months ago - GuruFocus